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Plasma membrane vacuolar H-ATPase (V-ATPase) activity
of tumor cells is a major factor in control of cytoplasmic and
extracellular pH and metastatic potential, but the isoforms
involved and the factors governing plasma membrane recruit-
ment remain uncertain. Here, we examined expression, distri-
bution, and activity of V-ATPase isoforms in invasive prostate
adenocarcinoma (PC-3) cells. Isoforms 1 and 3 were the most
highly expressed forms of membrane subunit a, with a1 and a3
the dominant plasmamembrane isoforms. Correlation between
plasmamembrane V-ATPase activity and invasiveness was lim-
ited, but RNAi knockdown of either a isoform did slow cell pro-
liferation and inhibit invasion in vitro. Isoform a1 was recruited
to the cell surface from the early endosome-recycling complex
pathway, its knockdown arresting transferrin receptor recy-
cling. Isoform a3 was associated with the late endosomal/lyso-
somal compartment. Both a isoforms associated with accessory
protein Ac45, knockdown of which stalled transit of a1 and
transferrin-transferrin receptor, decreased proton efflux, and
reduced cell growth and invasiveness; this latter effect was at
least partly due to decreased delivery of the membrane-bound
matrix metalloproteinase MMP-14 to the plasma membrane.
These data indicate that in prostatic carcinoma cells, a1 and a3
isoform populations predominate in different compartments
where they maintain different luminal pH. Ac45 plays a central
role in navigating the V-ATPase to the plasma membrane, and
hence it is an important factor in expression of the invasive
phenotype.
The vacuolar H-ATPase has emerged as a significant con-
tributor to net proton efflux from tumor cells (1–4). This
1-MDa membrane complex, comprising the soluble catalytic
V1 domain coupled to an integral membrane domain Vo, uses
the free energy of cytosolic ATP hydrolysis to pump protons
across membrane bilayers (5, 6). Also a ubiquitous component
of endomembranes, the V-ATPase acidifies compartments
involved in all stages of vesicular transport (6). Plasma mem-
brane V-ATPases are not unique to tumor cells and also play
crucial roles in acid efflux from osteoclasts, epididymal clear
cells, and renal intercalated cells (7, 8).
The ATP-hydrolyzing V1 domain contains subunits A–H in
a stoichiometry (AB)3CDE3FG3H. Vo translocates protons
across themembrane and consists of a, d, and e subunits linked
to a 6–10-member ring of c subunits. Operating as a rotary
motor, proton translocation is postulated to take place at the
dynamic interface of the a subunit and c-ring in the membrane
(see Ref. 5 and references therein). In higher eukaryotes, most
subunits occur as multiple isoforms (9, 10). For many, a com-
mon ubiquitous form predominates with others expressed at
high levels in particular tissues. The B1 subunit (ATP6V1B1),
for example, is highly expressed in kidney, with naturally occur-
ringmutations causing distal renal tubular acidosis, whereas B2
is ubiquitously expressed (11). Vertebrates express subunit
a isoforms 1–4 (plus additional splice variants) that have
47–61% sequence identity (12, 13). Although individual sub-
unit a isoforms are particularly highly expressed in some cells,
multiple forms are generally present and targeted to specific
compartments (14, 15). Targeting may be a function of the
cytoplasmic N-terminal domain of the protein, as it is in the
budding yeast Saccharomyces cerevisiae (16). The a1 form
(ATP6V0A1) appears ubiquitous, with some variants particu-
larly abundant in neuronal tissue (17), whereas a3 (ATP6V0A3)
is highly expressed in osteoclasts and macrophages (14, 18).
The predominant species in cells of the kidney andmale repro-
ductive tract is a4 (19, 20). The a2 form has been detected in
early endosomes (21) and in theGolgi complex (14, 22, 23), with
mutations causing the glycosylation defects and aberrant traf-
ficking that are characteristic of the disease cutis laxa (22). The
a3 form is found in late endosomes/lysosomes of cells of mono-
cytic lineage from where it is recruited to the ruffled border
zone of the plasma membrane of active osteoclasts or to the
maturing phagosome of macrophages (14, 18). In pancreatic
-cells, a3 is targeted to insulin-secreting granules (24),
although the a1 form has been identified in secretory vesicles in
neuroendocrine PC12 cells (23). The a1 isoform is also found in
synaptic vesicles of neuronal cells (17), performing the follow-
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ing two distinct roles: proton pumping to energize neurotrans-
mitter loading into vesicles, and Ca2-regulated vesicle fusion
with the plasma membrane involving Vo interaction with the
R-SNARE synaptobrevin (VAMP2) (25, 26). Consequently, Vo
containing subunit a1 is likely to appear at least transiently at
the plasma membrane of neuronal cells (17), although not nec-
essarily actively coupled to V1. The a1, a3, and a4 forms are also
featured at the plasma membrane of kidney proximal tubule
cells, in which a2 appears to be localized to early endosomes
(21). In renal intercalated cells and epididymal clear cells, a4 is
targeted to the apical membrane (27). Currently, little is known
about either the functional differences between subunit iso-
forms or the rules governing the interactions theymake, but it is
feasible that eukaryotic cells could assemble a wide variety of
V-ATPase complexes with potentially different functional
properties, locations, and inhibitor sensitivity.
PlasmamembraneV-ATPase activity is linked to growth and
invasiveness of a number of neoplastic cell types, including
breast (1, 3, 28, 29) and prostate (30, 31). Expression of the
subunit a3 isoform is higher in invasive melanoma cells com-
pared with non-invasive controls (32), and the same subunit is
also implicated in invasiveness of breast cancer cells (33). The
a4 subunit is highly expressed in some gliomas (34). V-ATPase
activity is proposed to contribute to tumor cell invasiveness and
growth via the following three mechanisms: first, maintaining
the acidic extracellular pH (pHex) promotes activity of cathep-
sins and activation of matrix metalloproteases (30, 32, 35, 36)
that can remodel the ECM6 to facilitate tumor cell extravasa-
tion and invasion of adjacent tissues; second, by contributing to
the stability of the abnormally alkaline cytosolic pH (pHcyt)
of tumor cells (37), the V-ATPase helps the cell evade acidosis-
induced apoptosis (38, 39); and third, V-ATPase activity facili-
tates sequestration of some chemotherapeutic drugs in intra-
cellular compartments leading to drug resistance (29, 40, 41).
The sensitivity of tumor cells to loss of V-ATPase function has
fueled interest in the enzyme as a therapeutic target in cancer
(42, 43), but the ubiquitous nature of the enzymemakes specific
targeting of cancer cells problematic. Vo subunit c binds bafilo-
mycin and other lipid-soluble inhibitors (44, 45), but a role for
subunit a in inhibitor binding is also likely (46, 47), opening the
possibility of discriminatory isoform-specific inhibitors. To
support such development,more information is required about
the differential expression, relative levels of activities, and func-
tional roles of the different isoforms in cancer cells.
In this study, we have examined the expression of subunit a
isoforms in prostatic carcinoma cells and examined their relative
contributions to proton efflux activity across the plasma mem-
brane.UsingRNAi,we looked at the functionof different isoforms
in endocytotic processes such as plasmamembrane receptor recy-
cling. The accessory subunit Ac45 has been proposed to be a pri-
mary factor in V-ATPase relocation to the plasmamembrane (48,
49) and in Ca2-regulated exocytosis (50). Here, we investigated
the association of this polypeptide with different subunit a iso-
forms and the consequences of its depletion on V-ATPase local-
ization and function in prostate carcinoma cells.
Experimental Procedures
Cell Culture—PC-3 (derived from a grade IV prostatic ade-
nocarcinoma bonemetastasis) and LNCaP (lymph nodemetas-
tasis of prostatic carcinoma) epithelium-like cell lines obtained
from ECACC were cultured in Ham’s F-12 and RPMI 1640
media, respectively, supplemented with 7% fetal bovine serum
and 2 mM glutamine. Cultures were incubated at 37 °C under
5% CO2. For transfer to microphysiometry and invasion assay
supports, the adherent cells were released by treatment with
Accutase (PAA Laboratories). Two cultures of PC-3 cells used
at different stages in this study were both validated by STR
profiling (Public Health England Cell Line Authentication Ser-
vice, Porton Down, UK).
RNAi Treatment—Cells cultured in 6-well plates were
treated with 19-mer siRNAs targeted against Ac45 (Thermo
Scientific-Dharmacon SMARTpool M-021378-00, 25 nM),
ATP6V0A1 (Thermo Scientific-Dharmacon SMARTpool
M-017618-00, 100 nM), ATP6V0A3 (Thermo Scientific-Dhar-
macon SMARTpool M-012198-00, 100 nM), and ATP6V1A1
(Thermo Scientific Dharmacon SMARTpool L-017590-01, 50
nM). A control siRNA (Thermo Scientific-Dharmacon non-tar-
geting pool D-001810-10) was also used at 100 nM. The four
constituent siRNAs within each pool were also tested individ-
ually for effects on expression and for phenotypic effects. As an
additional negative control, a representative siRNA from each
pool was tested after custom synthesis (Thermo Scientific-
Dharmacon) to include nucleotide changes as underlined:
a1, caacaucucaguaaugcua; a3, cccucgcgcagcacaagua; Ac45,
ccaccugucaacguaguuu).
The siRNAs were incubated with DharmaFECT-2 transfec-
tion reagent (Thermo Scientific) in serum-free medium for 45
min at room temperature before mixing 1:4 with complete
medium (7% fetal bovine serum). Cells were treated with the
siRNAmixture for 24 h before replacementwith fresh complete
medium. Where necessary for certain assays (invasion, micro-
physiometry), cells were transferred after this time and used
within the subsequent 24 h.
Microphysiometry—Measurements of extracellular acidifica-
tion rate (ECAR) were performed using a Cytosensor micro-
physiometer (Molecular Devices). Adherent PC-3 cells (105
cells per cup) were seeded directly into the microphysiometer
capsule cups and cultured for 48 h as above to allow an adherent
monolayer to form. Weakly adherent LNCaP cells required
embedding in agarose to prevent detachment from the capsule
membrane. Cupswere placed in the sensor chamber containing
perfusion buffer (nominally bicarbonate-free Hanks’ basal salt
solution (HBSS) without HEPES, pH 7.4). For sodium-free
HBSS, NaCl was replaced with 138 mM choline to maintain
osmolarity. The flow chamber formed between cell monolayer
and insert (effective volume 2.6 l) was circulated with perfu-
sion buffer at 37 °C at a rate of 100 l min1. A pump cycle of
40 s off and 80 s on was used. Typically, cells reached a steady
state ECAR after 30–40 min. Rates of acid accumulation are
computed by the Cytosensor software as the least squares fit to
the raw voltage time trace recorded when the pump is off, and
6 The abbreviations used are: ECM, extracellularmatrix; ECAR, extracellular acidi-
fication rate; ERC, endosomal recycling complex; HBSS, Hanks’ basal salt solu-
tion; TfR, transferrin receptor; V-ATPase, vacuolar H-ATPase; Tf, transferrin.
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the derived data are expressed as the change in ECAR as a func-
tion of time. Buffering capacity of the perfusion buffer, equili-
brated with atmospheric CO2 at 37 °C, was determined by
titrating change in pH with increasing concentrations of HCl.
Titration curveswere linear across the pH range spanned by the
experiments. Rates of proton efflux (JH, in nMHmin1) were
calculated by first converting ECAR into a rate of change of pH
(using theNernst equation) and then calculating the increase in
H concentration assuming a starting concentration of 40 nM,
pH 7.4. Because the buffering capacity of the perfusionmedium
was negligible, JH was not corrected for any buffering effects.
At 37 °C, a change in pHex of 1 pH unit min1 is equivalent to a
rate of change in potential of 61 mV s1.
Inhibitorswere perfused into the assay chamber via electron-
ically switchable valves. Bafilomycin A1, concanamycin A, and
ethylisopropylamiloride (Sigma) were introduced from freshly
made stock solutions in DMSO. This vehicle had no measur-
able effects on ECAR.
Cell Proliferation Assay—Cells were plated at a density of 1
104 cells/well in a 96-well plate (CellCarrier-96, PerkinElmer
Life Sciences) and allowed to adhere for 4 h. Cells were then
transfected with siRNAs as above. After culture for 48 h, live
cell numbers (relative to control) were determined by uptake of
calcein acetoxymethyl ester (calcein-AM; 2.5 M, 60 min incu-
bation at 37 °C in HBSS buffer). Fluorescence was measured in
a FlexStation 3 (Molecular Devices) with excitation at 490 nm
and emission at 520 nm.Numbers of dead cells (as a percentage
relative to controls) were determined fluorometrically by pro-
pidium iodide uptake (excitation at 535 nm and emission at 617
nm).
Invasion Assays—Cell migration through basement mem-
brane extract was assayed using Cultrex basement membrane
extract cell invasion assay in a 24- or 96-well plate format
(Trevigen Inc., Gaithersburg, MD). Cells were starved over-
night in serum-freemedium, detached by treatmentwithAccu-
tase, and resuspended in serum-free medium to give 106 live
cells ml1. In the final assay setup, each upper well of the mod-
ified Boyden chamber contained 5 104 cells (24-well format)
or 0.5 104 cells (96-well format). To test the effects of conca-
namycin, the inhibitor was added to an aliquot of the cell sus-
pension to give a final concentration of 1M in the upper cham-
ber (0.5% v/v DMSO, also included in control wells). Soluble
recombinant receptor activator of nuclear factor B ligand
(PeproTech, London,UK)was used at 10gml1. As chemoat-
tractant, the bottom well of each chamber contained medium
supplementedwith 10%FBS. Plateswere incubated at 37 °C (5%
v/v CO2) for 24 h, after which time any cells that had passed
through the basementmembrane extract/polycarbonatemem-
brane were detached. Cells were quantified by incubating with
calcein-AMandmeasuring the internalized fluorescence signal
in a plate reader accessory attached to a Cary Eclipse scanning
fluorimeter or FlexStation 3 (excitation at 485 nm and emission
at 520 nm).
Immunoprecipitation and Immunoblotting—Antibodies used
in this study were as follows: mouse anti-subunit A (H-00000523-
M02; Abnova Inc., Taiwan) recognizing residues 508–618 of
human ATP6V1A; rabbit anti-a1 (sc-28801, Santa Cruz Biotech-
nology Inc., Dallas, TX) recognizing residues 71–210 of human
ATP6V0A1; rabbit anti-a1 (AP5109A, Generon, UK) recognizing
residues 44–71 of human ATP6V0A1; mouse anti-a2
(H00023545-A01, Abnova Inc.) recognizing residues 198–304 of
human ATP6V0A2; rabbit anti-a3 made in-house against a pep-
tide comprising residues 689–707 of human ATP6V0A3; rabbit
anti-a4 (ab55827, Abcam, UK) recognizing the C-terminal resi-
dues of human ATP6V0A4; mouse anti-Ac45 (H00000537-M01,
Abnova Inc.) recognizing residues 51–151 of human ATP6AP1;
goat anti-ATP6V1F (sc-21220, Santa Cruz Biotechnology, Inc.)
recognizing a C-terminal peptide of V1 subunit F; rabbit anti-
MMP-14 (AB8102, Millipore (UK) Ltd., Watford, UK), recogniz-
ing catalytic domain residues 91–246;mouse anti-CD71 (transfer-
rin receptor; sc-65887, Santa Cruz Biotechnology, Inc.); mouse
anti-LAMP-1 (MA1–164, Thermo Fisher); sheep anti-TGN46
(51); and mouse anti-tubulin (T6199 (clone DM1A), Sigma).
Whole cell lysates were prepared by solubilization in RIPA buffer
(20mMTris-HCl, 150mMNaCl, 1mMNa-EDTA,1mMEGTA,1%
w/v Nonidet P-40, 0.5% sodium deoxycholate, protease inhibitor
mixture), centrifugation at 13,000 rpm inamicrocentrifuge at 4 °C
followedbyheating to80 °C for10min.Theproteinconcentration
was determined using the BCA method, and the concentration
was adjusted to 1mgml1 with RIPAbuffer. For immunoprecipi-
tation, cells cultured in 6-well plates were washed twice with PBS
containing Mg2 and Ca2 (PBS-Mg/Ca) before extraction into
RIPA buffer by incubation on ice for 20 min. Cell lysates were
centrifugedat 100,000 g for 20minat 4 °C in aBeckmanOptima
ultracentrifuge to remove insolublematerial. The protein concen-
trationof the cell lysateswas assayed, and the volumewas adjusted
with RIPA buffer to give 1 mgml1 protein. For immunoprecipi-
tation, 50 l of rabbit anti-a3 antiserum or 2 g of anti-a1 rabbit
IgGwereadded to0.4mlof cell lysate,whichwas then incubatedat
4 °C for 6 h on a shaking platform. Pre-immune rabbit serumwas
used as a control. The ImmunoCruz IP/WB Optima B system
(Santa Cruz Biotechnology) was used to precipitate antibody-
bound proteins where subsequent detection of co-precipitated
Ac45 andA1was performedwithmouse antibodies. For detection
of a1 and a3, antibody-protein complexes were precipitated by
incubation with protein-A/G agarose (Thermo Scientific) for 2 h
at 4 °C.
Bead-antibody-protein complexes were recovered by low
speed centrifugation, and the pelleted beads were washed three
times with RIPA buffer. These were then incubated with SDS-
PAGE sample buffer (NuPAGE LDS sample buffer; Life Tech-
nologies, Inc.) and heated to 90 °C for 10 min before separation
on 4–12 or 10% acrylamide NuPAGE gels (Life Technologies,
Inc.). For immunoblotting, protein gels were blotted onto poly-
vinylidene difluoride membrane and probed with HRP-conju-
gated goat anti-mouse or anti-rabbit IgG as appropriate.
Chemiluminescent signal was captured using a LAS-3000
imaging work station (Fuji Corp., Japan). Exposure times were
typically 2 min, with the exception of the a4 antibody where
the detectable signal necessitated 20min of exposure (see Fig. 2,
B and E). The signal from all immunoblots was within the
dynamic range of the imaging workstation.
Extraction of Biotinylated Cell Surface Proteins—Cells grown
on 6-well plates were washed three times with PBS-Mg/Ca and
then incubated on ice on a rocking table for 60 min with a
solution of 0.2 mg ml1 EZ-Link sulfo-NHS-SS-biotin
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(Thermo Scientific) (from fresh 20mgml1 stock in DMSO) in
PBS-Mg/Ca. Cells were then incubated for 20minwith ice-cold
PBS-Mg/Ca containing 100 mM lysine. After aspirating the
lysine solution, cells were extracted into RIPA buffer and incu-
bated on ice for 30 min.
To extract a total membrane fraction, cell monolayers from
two 175-cm2 tissue culture flasks were recovered by scraping
into PBS (supplementedwith protease inhibitors), sonicated on
ice for 60 s, and centrifuged at 10,000 g for 20min at 4 °C. The
supernatant was then centrifuged at 100,000 g for 1 h at 4 °C.
The pellet corresponding to a total membrane fraction was
resuspended in PBS containing 0.2 mg/ml EZ-Link sulfo-NHS-
SS-biotin and incubated on ice for 60 min before addition of
lysine (100 mM). The membranes were then recovered by cen-
trifugation at 100,000  g as above, washed with PBS, and
finally resuspended in RIPA buffer before incubation on ice for
30 min.
For recovery of biotinylated proteins, RIPA buffer extracts
were centrifuged at 100,000  g for 20 min and then added to
magnetic StrepTactin beads (Qiagen) pre-equilibrated with
RIPA buffer. Beads were agitated for 60min at 4 °C, then recov-
ered using a magnet, followed by two washes with RIPA, one
washwith 0.2RIPA (RIPAbufferwith 0.2%w/vNonidet P-40,
0.1% w/v sodium deoxycholate). The recovered beads were
incubated at 90 °C with SDS-PAGE sample buffer, separated by
SDS-PAGE, and probed by immunoblotting as above.
To monitor recycling of plasma membrane proteins, cells
were cultured, washed, and labeled with sulfo-NHS-SS-biotin
as above. After biotinylation and quenchingwith lysine, control
cells (representing a maximally surface-labeled fraction) were
removed into RIPA buffer. Internalization of biotinylated sur-
face proteins was initiated by replacing cold PBS-Mg/Ca with
HBSS warmed to 37 °C. At 5–120-min time points, residual
surface biotin was removed by incubation with 100mM sodium
2-mercaptoethanesulfonate (MESNa) (in 100 mM NaCl, 1 mM
EDTA, 0.2% w/v BSA, 50 mM Tris-HCl, pH 8.6) on ice for 15
min with gentle rocking. MESNa was then quenched by wash-
ing with ice-cold 100 mM iodoacetamide in PBS-Mg/Ca. Cells
were suspended in ice-cold PBS by aspiration and counted in a
hemocytometer. Cells were then recovered by centrifugation
(5000 g, 10min, 4 °C) and extracted into RIPA buffer with the
volume adjusted according to cell count to give an equivalent
volume per cell. This suspension was incubated on ice for 30
min. Lysates were centrifuged at 100,000 g for 20 min (4 °C),
and biotinylated proteins within the supernatants were bound
to magnetic StrepTactin beads, washed, and analyzed by SDS-
PAGE/immunoblotting as above.
Vesicular pH Assay—Cells were grown in 24-well plates and
incubated with FITC-dextran ((Sigma) 0.5 ml, 0.2 mg ml1) in
PBS (with Mg2 and Ca2) for 10 min at 37 °C. Total uptake
was determined by washing cells three times with PBS-Mg/Ca
at 4 °C, before harvesting by aspiration. Cells were resuspended
in PBS with 100 mM KCl and 10 M nigericin and placed in a
96-well fluorimeter plate, and the fluorescence was determined
in a Cary Eclipse fluorimeter with excitation at 490 nm and
emission across the 510–560-nm range. To determine vesicu-
lar pH, after washing with PBS-Ca/Mg, cells were incubated
with HBSS at 37 °C. At time intervals of 5–60 min, cells were
recovered into PBS and placed in 96-well fluorimeter plate, and
the excitation spectrum in the 400–500 nm range was obtained
for emission at 520 nm (3 scan average, excitation slit 2.5 nm,
emission slit 5 nm, 1200 nm min1 scan speed). The time-de-
pendent change in the ratio of excitation at 492 nm to that at
442 nm for 520-nm emission was then calculated. For calibra-
tion, cells were resuspended in PBS, 100 mM KCl, 10 g ml1
nigericin with 25 mMMES, 25 mMMOPS with the pH adjusted
to 5, 6, 7, or 8 with KOH.
Fluorescence Microscopy—For fluorescence microscopy, cells
were grownonpolylysine-treated coverslips until 70–80%con-
fluent. Coverslips were washed three times with PBS-Ca/Mg
before fixing with 4%w/v paraformaldehyde in PBS-Mg/Ca (10
min, room temperature). Paraformaldehyde was quenched by
adding NH4Cl to 50 mM in PBS (10 min at room temperature),
followed by washing with PBS. Cells were permeabilized with
1%w/v Triton X-100, 1%w/v fish skin gelatin in PBS for 10min
at room temperature, then incubated with 1:250 dilution of
anti-a3 polyclonal antiserum or with 5 g ml1 purified anti-
bodies for 1 h at room temperature. ForMMP-14 labeling, Tri-
ton X-100 was omitted. Cells were then washed two times with
PBS (20 min each) and then with 1:250 dilution of normal goat
serum in PBS. After briefly washing with PBS, Alexa-488-la-
beled goat anti-rabbit or Texas Red-labeled goat anti-mouse
antibodies (Life Technologies, Inc.) were added for 1 h at room
temperature, each also containing Hoechst 33258 (1 g ml1)
for nuclear staining. After washing three times with PBS (20
min each), coverslips were gently blotted and mounted onto
slides with Fluoromount G (Southern Biotech), then gently
sealed with acrylic, and stored in dark at 4 °C. For controls,
primary antibodies were replaced with pre-immune rabbit
serum or with purified rabbit or mouse control IgG.
Images were acquired using a DeltaVision deconvolution
microscope controlled by the SoftWorx suite of programs at
60 magnification. After locating upper and lower sections of
each cell, image stacks in the z-plane were collected typically as
2–3-m sections at three excitation/emission settings (for
Hoechst 33258, Alexa-488, and Texas Red/Alexa-594). Image
acquisition settings (exposure time, filter settings, pixel bin-
ning, and excitation power) were kept constant for all images to
allow valid comparison and quantitation. Image deconvolution
was performed using the corresponding function in SoftWorx.
Images of anti-MMP-14 antibody-labeled cells were collected
on an EVOS FI inverted digital microscope (Life Technologies,
Inc., Paisley, UK).
Pixel coincidence in double-labeled images was quantified
using the “co-localization” function of the image analysis soft-
ware Imaris (Bitplane AG, Zurich, Switzerland). For each chan-
nel, background fluorescence was set at 10% of the total signal.
Nonspecific binding of controlmouse and rabbit IgG and rabbit
pre-immune serumwere tested but gave negligible signal using
the image acquisition settings used consistently for collecting
data. Texas Red anti-mouse and Alexa-488-rabbit secondary
antibodies were tested, respectively, for their species cross-re-
activity to the rabbit (a1 and a3) and mouse (Ac45/TfR/LAMP-
1/A) primary antibodies, but again the negligible signal was
detected.
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Transferrin Uptake Assay—Cells were grown on glass cover-
slips as above and incubated in serum-free medium for 2 h.
Cells were then incubated with Alexa-594-conjugated human
transferrin (Molecular Probes, Life Technologies, Inc.) at 25g
ml1 on ice for 30 min. As a control, a set of coverslips was also
pre-treatedwith the endocytosis inhibitorDynasore (80M) for
30 min before exposure to transferrin. Cells were then washed
twice with ice-cold PBS-Mg/Ca to remove excess transferrin.
“Time0” cellswere immediately fixed formicroscopywithpara-
formaldehyde as above. Transferrin transport was initiated by
addition of HBSS warmed to 37 °C, and the cells weremoved to
an incubator. Coverslips were removed at time points 30–90
min, washed briefly with PBS-Mg/Ca, and processed for
microscopy as above, with additional staining for the a1 subunit
and with Hoechst 33258. Images were captured using the Del-
taVision microscope with fixed acquisition parameters
throughout. For each time point, images of 18–30 cells were
collected. Quantitation of Alexa-594-tranferrin fluorescence
was performed using ImageJ software (rsb.info.nih.gov).
Gene Expression Profiling—RNA was isolated from PC-3 cells
using RNeasy micro-extraction kit (Qiagen, Germany) and quan-
tified, and the purity was determined bymeasuring absorbance at
280, 260, and 230 nm using an ND-1000 nanodrop spectropho-
tometer (LabTech International, UK). After reverse transcription,
cDNA was subjected to microarray analysis using the Human
Genome U133 Plus 2.0 array (Affymetrix, High Wycombe, UK).
Gene expression levels were analyzed using Microarray Suites
software. Sequences used in the design of this array were selected
from the GenBankTM, dbEST, and RefSeq databases.
Results
V-ATPase Activity at the PlasmaMembrane—The contribu-
tion of the V-ATPase to proton extrusion activity across the
plasma membrane of prostatic carcinoma cells (ECAR) was
measured by microphysiometry after exposure to concanamy-
cin. Two different PC-3 and LNCaP prostate cell lines were
compared for correlation between V-ATPase activity and inva-
sive phenotype. Mean basal rates of H pumping across the
plasma membrane of PC-3 prostate cells gave a drop in extra-
cellular pH of 0.32 pH units min1, equivalent to a proton
pumping rate (JH) sufficient to change the proton concentra-
tion in the microphysiometer chamber by 43 nM min1 (Table
1). Non-invasive LNCaP prostate cells displayed mean rates
that were not significantly different from this (38 nM min1;
Table 1). Measurement after infusing with varying concentra-
tions of concanamycin (Fig. 1A) caused a drop in proton extru-
sion rates (t1⁄212 min), reversed by washing out the inhibitor
(recovery t1⁄2 40 min). For PC-3 cells, the maximal extent of
inhibition by concanamycin indicates that 40 14%of the basal
JH is V-ATPase-dependent (Fig. 1B). We found a small but
significant difference (p  0.05) in the relative contribution of
V-ATPase activity to JH of non-invasive LNCaP cells (29 
6%, Fig. 1B). Infusion with the Na/H exchanger inhibitor
ethyl isopropylamiloride at 100 M blocked 30 and 34% of JH
of PC-3 and LNCaP cells, respectively (Fig. 1B). Similar
decreases in JH were observed when measurements were made
with nominally sodium-free perfusion medium (Table 1).
Although the apparent IC50 of 100 nM for concanamycin in both
cells types (Fig. 1C) is high compared with published values for in
vitro effects, such an elevated value is not unexpected for a cell-
based assay and is below the concentration at which V-ATPase
specificity is lost (52).
Having established that theV-ATPase is amajor contributor to
proton efflux across the plasmamembrane of prostatic carcinoma
cells, the relative levelsof expressionof subunit isoformsthatcould
contribute to this activity were examined by gene array chip anal-
ysis (Fig. 2A). In PC-3 prostate cells, isoform B2 with subunit A
predominates in the catalyticV1domain, alongwithC1, E1, andG1
forms of the stator network subunits. Unexpectedly, the E2 iso-
form reported to be expressed exclusively in spermatids was also
present at relatively high levels (Fig. 2A). Among Vo subunits, the
d1 isoformwas highly expressed alongwith the a1 and a3 forms of
the large integral membrane component of the V-ATPase stator.
The a2 isoform was expressed at low levels, and the a4 kidney-
specific isoformwas apparently absent.High levels ofmRNAtran-
script encoding subunits D, F, H, c, and Ac45 were also detected
(Fig. 2A).Note thatalthoughcomparisonsof levelsof transcript for
unrelated subunits are meaningless, comparisons between iso-
forms (presumed to have similar transcript length and stability)
remain valid.
On the basis that a1 and a3 appeared to be the dominant
membrane subunit isoforms, these were examined individually
for their localization to the plasma membrane. To validate an
assay for plasmamembrane expression, surface biotinylation of
PC-3 prostate cells with a membrane-impermeable cleavable
biotinylation compound (sulfo-NHS-SS-biotin) was tested, fol-
lowed by pulldown with StrepTactin beads. This generated a
fraction that did not contain the late endosome/lysosome
marker LAMP-1 and only very low levels of the Golgi marker
TGN46 (Fig. 2B). Hence, we concluded that it represented
exclusively a plasma membrane-enriched fraction. Only negli-
gible binding of non-biotinylated proteins to the StrepTactin
beads was observed. This fraction showed signal on immunob-
TABLE 1
Rates of proton extrusion from prostatic carcinoma cells
Cell type Medium ECAR
pH
decreasea JH, obs
V s1 units min1 nM min1 (%)
PC-3 Na-HBSS 320 40b (n 10) 0.32 0.04 43.3 5.4 (100)
PC-3 Choline-HBSS 211 78 (n 13) 0.21 0.08 28.6 10.6 (66)
LNCaP Na-HBSS 283 61b (n 9) 0.28 0.06 37.9 8.3 (88) (100) c
LNCaP Choline-HBSS 184 52 (n 6) 0.18 0.05 24.4 7.0 (56) (64)c
aData are from an initial pH of 7.4 (40 nM H).
b tobt 1.56, p	 0.05, not different (two-tailed t-test).
c Relative rates are for LNCaP cells.
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lots for both a1 and a3, along with V1 subunit A and Ac45 (Fig.
2B). Isoform a1 was detected with an antibody recognizing res-
idues 71–210 (that has 32% identity with the corresponding
part of a3) and a3 with an antibody raised against a peptide of
residues 689–707 (11% identity to the corresponding a1 region)
(53). Contrary to the expression data, the a4 isoform was also
detectable in the totalmembrane fraction after long exposure of
the chemiluminescent immunoblot. It was not detectable in the
plasma membrane fraction when the protein loaded on the
immunoblot was equivalent to that in the other lanes in Fig. 2B,
but it was detectable at higher loading (discussed below). We
were not able to detect the a2 isoform by immunoblot in either
total membrane or plasma membrane fractions (data not
shown). These data indicate that both a1 and a3 V-ATPase iso-
forms are simultaneously present at the plasma membrane of
PC-3 cells.
To investigate isoform contributions to V-ATPase-depen-
dent proton extrusion, we established the conditions needed
for knockdown of V-ATPase subunit expression by RNA inter-
ference (RNAi) using synthetic inhibitory RNA (siRNA) oligo-
nucleotides. Pools of siRNAs and their four constituent siRNAs
were tested for effects on protein expression, along with a neg-
ative control version of one of the constituent siRNAs from
each pool (see “Experimental Procedures”). Although relatively
high siRNA concentrations (100 nM) and long transfection
times (24 h) were required,80% reduction in levels of a1 and
a3 was achieved as judged by immunoblotting (Fig. 2C). Ac45
(ATP6AP1) has been implicated in V-ATPase accumulation at
the plasma membrane of neuroendocrine cells (49) and in
directing the V-ATPase to the ruffled membrane of activated
osteoclasts, a specialized region of the plasma membrane (48).
In PC-3 prostate cells, Ac45 is not only present at relatively high
levels but also localized to the plasma membrane (Fig. 2B). To
examine the role of Ac45 in V-ATPase trafficking, Ac45 was
also subjected to RNAi knockdown, and the impact of this on
different V-ATPase functions was measured. Treatment with
25 nM siRNA for 24–48 h gave	90% depletion of Ac45 levels
(Fig. 2C). For a1, a3, and Ac45, treatment with a negative con-
trol mutant version of an siRNA from each pool resulted in no
significant loss of expression (Fig. 2C), underlining the specific-
ity of the expression knockdown. Depletion of subunit A
expression by	90% was also achieved after 24 h with 25 nM of
an siRNA pool (Fig. 2D).
Overall levels of a1 and a3 in the total membrane fraction
were not affected by subunit A knockdown (Fig. 2D), indicating
that Vo stability is not dependent on subunit A. Loss of subunit
F however implies complete disruption of V1 assembly. In a
mouse knock-out model, up-regulation of the B2 subunit can
compensate for loss of B1 (54), with some functional compen-
sation also possible between the subunit a homologues Vph1p
and Stv1p in Saccharomyces (55). Here, knockdown of either a1
or a3 did not result in a corresponding increase in the levels of
the other isoform at the plasmamembrane (Fig. 2E), suggesting
no compensatory mechanism. With 10-fold higher loading
than in Fig. 2B and long exposure, some signal for the a4 iso-
form was also detected, but levels were similarly unaffected by
knockdown of either a1 or a3. Depletion of these subunit iso-
forms did result in a decrease in the signal from subunit A
FIGURE 1. V-ATPase activity at the plasma membrane of prostate carci-
noma cells. A, example microphysiometry traces for PC-3 cells. Concanamy-
cin Awas added as indicated by the solid arrow andwashed out at the points
indicated by the open arrows. Solid triangles indicate vehicle only (DMSO);
open triangles indicate 50nM; solid circles indicate 100nM;open circles indicate
1M.B, relative contributionsof V-ATPaseandNHE1activities toHextrusion
by PC-3 (white, n 10 (three readings per measurement)) and LNCaP (gray,
n6 (3 cell samples permeasurement)) prostatic carcinomacellsweredeter-
mined as in A and expressed as the activity lost after addition of 2 M conca-
namycin A (V-ATPase contribution), 50 M ethyl isopropylamiloride (NHE1
activity), with the residual activity being the sum of other unassigned activi-
ties. Error bars represent the standard deviation for measurements with each
inhibitor (PC-3, n 10; LNCaP, n 6). Differences between relative V-ATPase
contributions to JH
 in the two cells types are not statistically significant (p
0.055, unpaired t test). C, inhibition curves for the concanamycin-sensitive
component of JH
 of PC-3 (solid circles) and LNCaP cells (open circles). Values
are expressed as the percentage of the concanamycin-sensitive activity in B
remaining after inhibitor addition. Error bars represent standard deviation of
each measurement (n 4). EC50 for both cells lines is100 nM.
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associated with the plasmamembrane fraction, consistent with
decreased assembly due to reduced availability of Vo. Ac45
knockdown had a similar effect on subunit A and a1 levels (but
no reproducible effect on a3) (Fig. 2E), consistent with a role for
the accessory subunit in V-ATPase delivery to the cell surface.
Intracellular Localization of V-ATPase Subunit Isoforms—
An investigation of the intracellular distribution of the
V-ATPase a1 and a3 subunits by immunofluorescence micros-
copy revealed distribution in different (but in part overlapping)
compartments (Fig. 3). Staining for the a1 isoformwas punctate
(consistent with its presence in small vesicles) and distributed
throughout the cytoplasm (Fig. 3,A–C). This stainingwas coin-
cident with that of TfR (CD71), a marker for the plasma mem-
brane and early endosomes (Fig. 3B), but notwith the late endo-
some/lysosome marker LAMP-1 (Fig. 3A). The converse
situation was observed with the a3 isoform; it showed much
FIGURE 2. Expression of V-ATPase subunit isoforms in PC-3 cells. A, extracted mRNA from PC-3 cells was reverse-transcribed and analyzed on Affymetrix
DNAmicroarrays (see “Experimental Procedures”). Mean values were determined from the output of two independent analyses. Columns indicating isoforms
of a particular subunit have equivalent shading. Subunits representedon the array byonly a single gene (A, c, D, e, F, H andAc45) have the same shading. Output
for the ATP6V0A1–4 genes is magnified in inset. B, to detect proteins accessible to the extracellular medium, intact PC-3 cells were labeled with membrane-
impermeable biotinylation reagent prior to solubilization and extraction with StrepTactin affinity beads, followed by immunoblot analysis (Surface). As a
control for reactivity, a detergent-solubilized membrane fraction was subjected to the same analysis (Membranes). Non-biotinylated protein gave negligible
binding to the StrepTactin resin (Control). The Membranes samples contain 20 g of total protein with the exception of the a4 blot, which contains 50 g.
Surface sample loading is the same in each blot, adjusted to give equivalent intensity in membranes and surface for Ac45. Chemiluminescence capture for a4
was 10-fold longer than for the other immunoblots. C, knockdown of a1, a3, and Ac45 expression by RNAi. PC-3 cell lysates (15g of protein) were analyzed by
immunoblotting (IB)with the corresponding subunit-specific antibody after transfectionwith isoform-specific siRNAs. Tubulin (Tub) levelswereused to ensure
equivalent loading. Individual siRNAs thatmake up eachDharmacon SmartPoolwere individually tested (siRNA1–4), alongwith the correspondingpool (Pool).
A version of siRNA-1 synthesized to include nucleotide changes as set out under “Experimental Procedures” was also tested (Mutant). D, RNAi knockdown of
subunit Adisrupts V1 assemblybutdoesnot affect subunitaexpression. A totalmembrane fractionwas isolated fromcells after transfectionwith an siRNApool
specific forATP6V1A. Laneswere loadedwith 30gof total protein and immunoblotted (IB) for Vo subunitsa1 anda3 andV1 subunits A andF. E,effects of siRNA
knockdown on levels of non-targeted subunits at the plasmamembrane. Cell surface proteins were extracted after biotinylation as in B from cells transfected
with siRNAs fora1,a3, andAc45. Biotinylated extract from1 10
5 cells (5 105 for subunita4)were analyzedby immunoblot (IB) fora1/3/4, subunit A, andAc45.
TfR was used as a loading control. Data capture for the a4 immunoblot was for 10 longer than for the other samples.
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greater coincidence with LAMP-1 than with TfR (Fig. 3, D and
E). Both a1 and a3 showed substantial co-distribution with
Ac45 and A (Fig. 3, C and F). Quantification of pixel co-distri-
bution in merged optical sections (Fig. 3, A–F) confirmed that
a1 predominantly co-localizes with TfR-enriched early endo-
somes, whereas a3 is predominantly associated with LAMP-1-
containing late endosomes/lysosomes (Fig. 3G). Both a1 and a3
showed95% co-distribution with A, suggesting relatively lit-
tle Vo detached from V1, and80% co-distribution with Ac45,
suggesting that themajority ofV-ATPaseswith either subunit a
isoform associates with this accessory subunit. On the basis of
these data, it appears that a1 and a3 exist largely in different
compartments of the endocytotic machinery, albeit with some
degree of overlap. Immunoprecipitation of detergent-solubi-
lized V-ATPase complexes (Fig. 3H) showed that antibodies to
either a1 or a3 isoforms co-precipitated Ac45 and A subunits.
Precipitates generated by pulldown with either anti-a antibody
gave no signal on immunoblots probedwith the antibody to the
other isoform (Fig. 3H), confirming that the respective antibody
probes were highly isoform-specific.
Functional Effects of RNAi Knockdown of V-ATPase Subunits—
Although PC-3 cells transfected with a non-targeting control
siRNApool andwithmutant versions of individual siRNAs prolif-
erated at essentially normal rates (doubling time of 48 h), cul-
tures of cells depleted for V-ATPase subunits were essentially
static (Fig. 4A). The transfected cells did however remain alive (as
judged by calcein-AM uptake), with no appreciable differences in
the proportion of dead cells between control and V-ATPase-de-
pleted cultures (4–5%; Fig. 4A). Cessation of growth after
V-ATPase knockdown serves to underline the importance of its
function in cell physiology.
The effects of RNAi knockdown of a1/a3 levels on the inva-
sive properties of PC-3 cells were also tested bymeasuring che-
motactic migration through an extracellular matrix extract
(Matrigel) (Fig. 4C). Knockdown of either a1 or a3 by individual
or pooled siRNAs strongly suppressed migration in this model
of metastatic potential, clearly indicating that both isoforms
make significant contributions to the invasive phenotype of
PC-3 cells. Mutations to inhibitory siRNAs from both a1 and a3
pools that permitted normal levels of expression also led to cells
FIGURE 3. Subcellular localization of the a1 and a3 subunits. A–F, immunofluorescencemicroscopy of fixed and permeabilized PC-3 cells. Left column, cells
stainedwithantibodies toa1 (A–C) ora3 (D–F).Center column, stainingwithantibodies toLAMP-1 (AandD), TfR (BandE), orAc45 (Cand F).Right column,merged
images of those in left and center columns, with coincident pixels colored yellow. Nuclei are stained with Hoechst 33258. Scale bars, 10 m (A and B) or 20 m
(C–F). G, quantitation of co-incident staining. Images such as those in A–F were analyzed using the Coincidence function of Imaris software. Values are
expressed as the percentage of pixels showing staining for a1 (open histograms) or a3 (gray histograms) that also stain for the subcellularmarker indicated. Error
bars represent standard deviation. The a3 isoform showed significantly greater (p  0.01) co-localization with the late endosomal marker LAMP-1 (38 cells
analyzed) than did a1 (26 cells analyzed), a1 co-localizing significantly more than a3 (p 0.05) with the plasma membrane/endosome marker TfR (23 and 27
cells, respectively). Both a1 and a3 showed strong co-localization with subunit A and Ac45 (11–24 cells analyzed). *, p 0.01; ***, p 0.001. H, both a1 and a3
associate with Ac45. The a1 and a3 subunit isoforms were immunoprecipitated (IP) from detergent-solubilized PC-3 cell lysate, and co-precipitating proteins
were analyzed by immunoblotting (IB). Precipitation with normal rabbit serum was used as a control for nonspecific binding. A sample containing the
equivalent amount of cell lysate to that used in the immunoprecipitations was also run (Input). In the immunoblot of the A subunit, the asterisk indicates
recognition of the heavy chain of the precipitating IgG. Ab, antibody.
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achieving normal levels of invasiveness (Fig. 4C), further indi-
cating the specificity of the RNAi effect.
Loss of invasiveness of breast cancer cells aftera3 knockdown
has previously been reported, with effects similar to those
caused by treatment with bafilomycin A1 (33). It is unclear
whether these effects are mediated via a decrease specifically
in JH or through broader cellular effects such as arrest of
trafficking. Pertaining to this, we have observed that the
cytokine receptor activator of nuclear factor B ligand has
no effect on JH, but the 50% increase in invasiveness it
causes is completely ablated by concanamycin A (data not
shown). Receptor activator of nuclear factor B ligand is
reported to increase invasiveness of prostate and breast can-
cer cells of epithelial origin via c-Src and MAPK signaling
pathways (56, 57). As discussed below, knockdown of a3 in
particular affects invasion to a much greater extent than it
does JH (Fig. 4B). Consequently, it is likely that the effects of
a1 and a3 knockdown are mediated via changes to trafficking
processes in the cell rather than to decreased acidification of
the extracellular environment.
Ac45 depletion by siRNA pool and by individual RNAs also
significantly decreased PC-3 cell invasiveness in vitro, although
invasiveness was unaffected by a mutant version of representa-
tive siRNA (Fig. 4C). This points to a role for Ac45 in navigating
FIGURE4.Effectsof siRNAknockdownonV-ATPase function inPC-3 cells.A,assayof live/deadcells after siRNA treatment. As in Fig. 1, individual siRNAs that
make up each pool were individually tested (siRNA1–4), along with the corresponding pooled siRNAs and mutant version. Numbers of viable cells 48 h after
siRNA transfectionweremeasured by calcein fluorescence and expressed relative to the change in number of cells in a control transfectedwith non-targeting
siRNA. Numbers of dead cells (as a percentage of the total) were measured by propidium iodide uptake (measurements made in duplicate or triplicate in
96-well format, repeated 4 times). B, effect of non-targeting (control) and a1, a3, and Ac45-specific siRNAs on concanamycin-sensitive H
 efflux. The concana-
mycin-sensitive activity remaining after siRNA treatmentwas determinedby adding the compound (2M) and expressed relative to the activity in control cells
(equivalent to the concanamycin-sensitive activity shown in Fig. 1B). Error bars indicate standard deviation of eachmeasurement (n 3, two cell samples per
measurement). Both a1 and a3 siRNAs significantly decreased the concanamycin-sensitive component of JH
 (a1, p 0.01; a3, p 0.05). C, a1, a3, and Ac45
siRNAs suppress the invasive phenotype of PC-3 cells. PC-3 cells were induced to migrate through Matrigel using FBS as chemoattractant. Cells treated with
siRNAs (two individual siRNAs fromeach pool, the complete four siRNApool and amutant version (detailed under “Experimental Procedures”)) were used 24 h
post-transfection. Cellsmigrating through theMatrigel layer were counted after 24 h, and numbers were expressed relative to the untreated PC-3 cell control.
Invasiveness of mock-transfected cells (Control pool) was not significantly different from untreated cells. PC-3 cells were significantly more invasive than a
non-invasive LNCaP control (p 0.001), and a1, a3, and Ac45 siRNAs (individual or pooled) all showed significantly decreased cell invasiveness (p 0.01; n
3, with three replicates per determination). D and E, uptake of FITC-dextran and measurement of vesicular pH. D, total uptake after 10 min measured as the
fluorescence emission at 520 nm for cells treated with siRNAs that were non-targeting pool (Control) or pools targeted to Ac45, a1, or a3 subunits. Error bars
show standard deviation (n 3). All targeting siRNAs caused significant effects (***, p 0.001). E, change in the vesicular pH experienced by the endocytosed
FITC-dextran, measured as the change in the 492 nm/442 nm excitation ratio for emission at 520 nm. Open circles, untreated cells; closed circles, 2 M
concanamycin; open triangles, control (non-targeting) siRNA; closed triangles, Ac45 siRNA. Closed and open squares, a1 and a3 siRNAs, respectively. Error bars
indicate standard deviation (n 3).
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both V-ATPase isoforms around the cell, a phenomenon we
investigated further in this study.
Knockdown of a1 levels eliminated 78 6% of the concana-
mycin-sensitive component of JH, whereas depletion of a3 lev-
els accounted for only 34  17% (Fig. 4B), indicating that it is
predominantly an a1-containing V-ATPase that contributes to
JH in these cells, with an a3 isoform making a much smaller
(but significant) contribution to this activity. Because efficiency
of RNAi knockdown of each isoform is broadly equivalent (Fig.
2C), the data in Fig. 4B suggest an2:1 split in the contribution
of the two isoforms to the bafilomycin-sensitive JH compo-
nent. We note however that the sum of effects of even incom-
plete a1 or a3 knockdown on plasma membrane V-ATPase
activity is 	100% inhibition, implying that a3 knockdown has
some influence on plasmamembrane activity of the a1-contain-
ing isoform and vice versa. This is not unexpected given the
dynamic inter-relationship between membrane compartments
within the cell. Depletion of Ac45 also caused a trend toward
loss of concanamycin-sensitive JH, but these measurements
were prone to high variance and hence the trend indicating 40%
loss of activity was not significant at the 95% confidence limit
(Fig. 4B).
Fluid-phase endocytosis was significantly reduced after
Ac45,a1, ora3 knockdownas indicated by a decreased uptake of
FITC-labeled dextran (Fig. 4D). However, neither the rate of
endosomal/lysosomal vesicular acidification nor the final min-
imum pH levels experienced by the dextran in vesicles were
significantly different from controls when a1 or Ac45 was
depleted by siRNA transfection (Fig. 4E). Only a3 knockdown
appeared to have any effect on this process, initially slowing the
rate at which the pH of FITC-dextran-loaded vesicles
decreased, but ultimately with no significant effect on the min-
imal pH achieved.
Requirement for V-ATPase Subunits in Endocytosis and
Trafficking—Substantial co-distribution of a1 with TfR implies
that they move together through the endosomal recycling sys-
tem. To examine this, we tested the impact of siRNA depletion
of a1 and a3 on TfR (CD71) recycling using a surface biotinyla-
tion protection assay. This involvesmembrane protein biotiny-
lation (on ice) of extracellular surface-exposed amine groups
with a membrane-impermeable but reversible (disulfide-con-
taining) reagent, followed by resumption of endocytosis by
incubation at 37 °C. Biotinylated membrane protein internal-
ization prevents removal of the biotin moiety by incubation
with a water-soluble reductant (MESNa); hence, pulldown of
the total biotinylated fraction from cell lysates reports on the
kinetics of endocytosis. For control cells, biotin removal indic-
ative of TfR re-exposure at the cell surface occurred with a
half-time of 45 min (Fig. 5, A and B). Transfection with
siRNAs targeted against the a1, a3, Ac45 (pooled or individual
siRNAs), or A soluble domain subunits had no significant effect
on the initial internalization, with broadly equivalent levels of
internalized TfR consistently seen up to 30 min after restart of
endocytosis (Fig. 5,A–C). However, knockdown of a1 andAc45
significantly slowed the rate of biotin removal from TfR, with
levels of receptor biotinylation remaining essentially constant
across the 120-min time course, indicating retention of the
receptor inside the cell. Treatment with an a3-depleting siRNA
pool caused some slowing ofTfR recycling, an individual siRNA
from that pool actually having amore clearly defined effect (Fig.
5, A and B). Depletion of a1 and Ac45 (and less conclusively a3)
therefore significantly slowed transit of TfR through the endo-
somal recycling system. Because of the non-catalytic role of Vo
in membrane fusion (58, 59), the observed effect could be due
either to loss of acidification or to inhibition of membrane
fusion events. Becausemembrane fusion should not be affected
by loss of V-ATPase catalytic activity, effects resulting from
RNAi knockdown of the catalytic subunit A can discriminate
between these possible mechanisms. Subunit A depletion (Fig.
5A) stalled TfR recycling in a similar way to a1 knockdown
without affecting levels of a1 in the membrane (Fig. 2D), and it
was indistinguishable from the effect of directly inhibiting pro-
ton pumping with bafilomycin A1 (Fig. 5, A and C). Arrest of
TfR recycling by a1 depletion is likely to bemediated via altered
vesicular acidification and not by direct effects on membrane
fusion. The siRNA effects appeared to be highly specific, with
mutant versions of expression-suppressing siRNAs having no
significant effects on TfR recycling.
The impact of Ac45 depletion on plasma membrane protein
recycling was further resolved using the surface biotinylation
assay. In control cells, TfR was internalized with a t1⁄2 of 15
min (Fig. 5, D and E), with loss of biotinylation after2 h con-
sistent with recycling back to the cell surface (or degradation).
Knockdown of Ac45 elicited a major change in uptake kinetics;
TfR internalization was slowed, with a t1⁄2 of45min; recycling
of TfR back to the plasma membrane could not be detected
even after 2 h (Fig. 5,D andE). A similar change in the dynamics
of subunit a1 internalization and recycling was also observed
(Fig. 5, D and E). Maximal a1 internalization in Ac45-depleted
cells occurred after 	2 h compared with 30 min in control
cells. These data indicate that the a1-containing V-ATPase,
although active at the plasma membrane, is endocytosed rela-
tively quickly in an Ac45-dependent manner.
The observed effect of Ac45 depletion on membrane cycling
to the cell surface could also impact the delivery/secretion of
ECM-degrading enzymes, offering an explanation for the
impact of Ac45 knockdown on PC-3 cell invasiveness in vitro
(Fig. 4C). To examine this further, we looked at the effect of
Ac45 depletion on delivery of the membrane-bound matrix
metalloprotease MMP-14 to the cell surface. Highly expressed
at the plasmamembrane of cancer cells (60),MMP-14 activates
collagenases leading to degradation of the ECM and is specifically
linked to cell invasiveness (61, 62). Here, using immunofluores-
cence labeling of non-permeabilized cells with an antibody
recognizing the extracellular region of MMP-14 (Fig. 5, F andG),
Ac45 depletion caused a significant decrease in antibody-acces-
sible protein at the cell surface (Fig. 5H). Disturbance
of V-ATPase dynamics through loss of Ac45 therefore not only
impacts the ability of the cell to sustain a low extracellular pH
(Fig. 4B) but also its ability to secrete ECM degrading activities.
Both are important factors in expression of the invasive
phenotype.
The effects of V-ATPase subunit depletion on transit
through the endosome-lysosome system were also monitored
by following time-dependent changes in the intracellular distri-
bution and total fluorescence signal of Alexa-594-Tf as a proxy
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FIGURE 5. Effects of subunita1,a3, andAc45depletiononTfR recyclingdynamics.A, recycling of the TfRwasmonitored using the surface biotinylation assay as
under “Experimental Procedures” in cells treated with non-targeting siRNA pool (Control); siRNA pools targeted to a1, a3, Ac45 (a1/a3/Ac45-pool); representative
individual siRNAs fromeachpool (a1/a3/Ac45-1); and thecorrespondingmutant versionof that siRNA (a1/a3/Ac45-mut). Tomonitor theeffects ofdisruptionofproton
pumping, cells were treated with an siRNA pool targeted to subunit A (V1-A) or pre-treated for 30 min with 100 nM bafilomycin A1 (Baf). After stripping residual
surface biotinylationwithMESNa, internalized biotinylated proteinswere extracted from solubilized cells by binding to StrepTactin beads. Internalized TfR retaining
biotin was detected by immunoblotting. B and C, quantitation of immunoblots as in A by densitometry. Values are expressed as a proportion (%) of the maximally
biotinylatedstateat time0.Errorbars indicate standarddeviationof themeanvalue (Control, n3).D,Ac45depletionarrests recyclingofplasmamembraneproteins.
Recycling of the transferrin receptor (TfR) and the a1 isoform was monitored after siRNA knockdown of Ac45 using a surface biotinylation assay as above. At the
specified time points, biotinylated proteins were extracted by binding to StrepTactin beads. Bound proteins were analyzed by immunoblotting, typical examples
being shown for transferrin receptor (D,upper panel) anda1 (D, lower panel). E,quantitationof immunoblotsbydensitometry.Open symbols, cells treatedwith control
(non-targeting) siRNA.Closed symbols, treatedwithAc45 siRNA. Values are expressed as a proportion of themaximally biotinylated state at time 0. Error bars indicate
standarddeviation(TfR,n5;a1,n3).F–H,Ac45depletiondecreasescell surfaceexpressionofMMP-14.Sample immunofluorescence imagesofnon-permeabilized
control (F) or Ac45 siRNA-transfected (G) PC-3 cells labeledwith an antibody recognizing the extracellular domainofMMP-14.Nuclei are stainedwithHoechst 33258.
Scalebar,20m.H,quantitationof the labeling in control andAc45-depletedcells. Fluorescence fromraw images (15 randomfields containing100cells fromthree
separate experiments) was quantified using ImageJ. ***, p 0.001.
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for its receptor, TfR (Fig. 6). After initial binding of labeled Tf
ligand for 30 min at 4 °C, cells showed characteristic labeling
of the cell periphery that was qualitatively similar regardless of
siRNA applied. Quantitatively, Ac45 knockdown decreased Tf
uptake by40% (Fig. 6A), with an even greater effect observed
upon knockdown of a1 (65% decrease) or a3 (64% decrease).
Treatment of control cells with the pharmacological dynamin
inhibitor “dynasore” (63) almost completely abolished Tf endo-
cytosis (Fig. 6A). Monitoring Alexa-594-Tf fluorescence over
time allowed Tf recycling and release from the cell to be mon-
itored (Fig. 6B). In control cells,54%of the signalwas lost over
a 90-min period. However, knockdown of Ac45 or a1 levels
caused the Alexa-594-Tf signal to decrease by no more than
12% over this period, consistent with retention of the labeled Tf
in the endosomal system. Depletion of a3 in the cell also
appeared to slow Tf recycling, although this effect was not as
pronounced as inAc45/a1-depleted cells. In control cells, inter-
nalized transferrin co-localized with a1 in large perinuclear
vesicular bodies (Fig. 6C, row 1), qualitatively similar to previ-
ous observations (64) and presumed to be recycling endosomes.
Cells in which Ac45 was depleted showed qualitatively similar
distribution of large Tf/a1-containing vesicles (Fig. 6C, row 2).
This infers that although transferrin uptake is decreased as a
result of Ac45 depletion (as shown in Fig. 6A) because TfR is
retained in the cell (Fig. 5, D and E), the endocytosed Tf ulti-
mately ends up in the same compartment as in control cells.
The key difference is that in the absence of Ac45, the large
vesicular bodies in which Tf accumulates recycle only very
slowly back to the cell surface. Hence, the effects of Ac45
knockdown appear to inhibit both internalization from the
plasma membrane and transit back to the cell surface.
Although the effects of depleting either subunit a isoform
showed broadly similar effects to Ac45 depletion by inhibiting
Tf endocytosis (Fig. 6A) and accumulation within intracellular
compartments (Fig. 6B), there were marked differences in the
intracellular distribution of internalized Tf. After 90 min, Tf
was still distributed throughout the a1-depleted cells in small
vesicular bodies, with partial co-localization with the residual
a1 subunit (Fig. 6C, row 3, arrows and inset). A similar distribu-
tion pattern was seen after a3 knockdown (Fig. 6C, row 4), with
some evidence for the presence of larger a1-containing vesicles
(inset and arrows). This was in contrast to the large perinuclear
vesicles evident in both control and Ac45-depleted cells, sug-
gesting that subunit a1/3 and Ac45 depletion exert their effects
at different stages in the endosomal transport process.
Discussion
In this study, invasive and non-invasive prostate carcinoma
cells supported high but essentially indistinguishable overall
rates of proton extrusion. The36% higher V-ATPase-depen-
dent component of this activity from invasive cells above that
from non-invasive was statistically significant, but this difference
appears too small to be a critical factor in defining the invasive
phenotype. In contrast to previous studies (31, 33), we conclude
that in theprostate carcinomacell lines examinedhere,V-ATPase
function at the plasma membrane differs little between invasive
and non-invasive cells. Consequently, we detect no direct correla-
tionbetweenplasmamembraneV-ATPaseactivity andmetastatic
potential. This does not mean that V-ATPase activity has no role
in invasiveness as it clearly does, given that inhibition by either
bafilomycin or RNAi has a significant impact on invasiveness (31,
33). Rather than being a feature that distinguishes invasive from
non-invasive cells, we suggest that plasma membrane V-ATPase
facilitates invasiveness by supporting ECM degradation via extra-
cellular acidification or transport/secretion of protease cargo (32,
65–67). This latter role is consistent with the observation that
Ac45 knockdown decreases invasiveness with only a small loss of
JH, presumably as a consequence of stalling transport processes
(discussed below).
Themicroscopy data andRNAi effects onTfR recycling indi-
cate that the a1 and a3 isoforms primarily operate in different
FIGURE6.Effects ofAc45expressionknockdownonendocytosis of trans-
ferrin. A, Alexa-594-Tf uptake by PC-3 cells treated with control (non-target-
ing), Ac45, a1- or a3-targeted siRNA pools. As negative control, cells were also
treated with the endocytosis inhibitor dynasore (Dyn). After washing off
excess transferrin, cells were fixed for microscopy, and the fluorescence from
raw imageswas determined (10–25 images) using ImageJ software. All treat-
ments resulted in significant (p0.01) loss of transferrin uptake. ***,p0.01.
B, time-dependent changes in Alexa-594-Tf fluorescence in siRNA treated
cells. After the initial transferrin loading, cells were returned to 37 °C before
fixing at different time points. Alexa-594-Tf fluorescence was determined as
inA.Closed circles, control (non-targeting) siRNApool;opencircles,Ac45siRNA
pool; closed triangles, a1 siRNApool;open triangles, a3 siRNApool.Onaverage,
20 images were captured and quantified for each time point for each siRNA
treatment. C, immunofluorescence microscopy of fixed and permeabilized
siRNA-treated cells 90 min after initiation of Alexa-594-Tf uptake, stained for
the a1 subunit (FITC, left column). Center column, Alexa-594-Tf fluorescence.
Right column, merged images with coincident pixels colored yellow. Insets
and arrows, details of vesicular structures showing coincident fluorescence.
Contrast has been adjusted to highlight qualitative aspects, but quantitation
was performed on raw images captured using constant microscope parame-
ters. Nuclei are stained with Hoechst 33258. Scale bar, 20 m.
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endosome populations. The distribution of the a1 isoform
within the cell strongly resembles that of TfR (Fig. 3), suggest-
ing that it also transits through early endosomes and recycles
back to the plasma membrane (68, 69). Bafilomycin brings
about rapid alkalinization of compartments along the endo-
some-lysosome route but has only a small effect on the rate of
TfR internalization from the plasmamembrane (70) or traffick-
ing of cargo from the sorting endosome to the endosomal recy-
cling compartment (ERC) (71, 72). In contrast, bafilomycin sig-
nificantly slows exit of cargo from the ERC (72), suggesting that
it is this stage in the recycling process that is most affected by
loss of V-ATPase activity after RNAi depletion of a1. The a3
form largely populates late endosomes/lysosomes, yet it also
traffics to the plasmamembrane. This isoform is recruited from
late endosomes/lysosomes to plasmamembrane-derived struc-
tures in macrophages and in osteoclasts via interaction with
microfilaments (14, 18, 73). A general role in secretory path-
ways has been proposed for this isoform (24) that could extend
to the prostatic epithelial cells examined here, where it could be
present on secretory lysosomes. It is noteworthy that both a1
and a3 knockdown decrease Tf internalization, slowing its tran-
sit through the endosome network. Depletion of either a sub-
unit also leads to significant differences inmorphology and intra-
cellular distributionofTfR/a1 vesicles comparedwith control cells
(and to Ac45-depleted cells, discussed below) visualized by anti-
body staining or chase of fluorescent Tf ligand through the trans-
port pathways. Complete and efficient trafficking of the Tf-TfR
complex through the endosomal system must therefore require
both a1 and a3 forms of the V-ATPase. Given that subunit A
knockdown leads to a slowing of TfR recycling similar to that seen
with a1 (and to a lesser extent a3), it seemsmost plausible that this
retention effect results from loss of V-ATPase activity. Of course
this does not exclude the possibility that loss of Vo resulting from
a1 (or a3) knockdown also prevents a final (ATPase-independent)
membrane fusion process at the plasma membrane perhaps
involving a connection to the R-SNARE.
In the degradative pathway, the movement of cargo from the
late endosome to lysosome (but not entry into the late endo-
some) is also dependent on V-ATPase activity (71, 74). Here,
knockdown of either a1 or a3 isoforms (also Ac45) had an effect
on this process, inhibiting the overall level of dextran uptake into
thecell.However, because thisFITC-dextranuptakewas inhibited
without any apparent alkalinization of the late endosomes/lyso-
some,we conclude that knockdownof theV-ATPasemust lead to
overall loss of cellular capacity for fluid-phase endocytosis and
transition to the lysosomebutwith the residualV-ATPase expres-
sion still sufficient to achieve normal luminal pH.
Recruitment of proteins to endosomal membranes is pH-de-
pendent (75, 76), and hence V-ATPase proton-pumping capac-
ity is important in defining the function of the compartment.
Here, a1 and a3 isoforms were differentially targeted to cellular
compartments that have different luminal pH (	6 for a1 in
early endosomes/ERC and 6 for a3 in late endosomes/lyso-
somes). An intriguing possibility is that the presence of a1 or a3
programs the V-ATPase to maintain a particular luminal pH.
This could result from perhaps different ATP/H coupling
ratios (77) or via a pH-sensing regulatory feedback system with
similarities to that proposed for the a2 subunit isoform (78).
The Vo-associated glycoprotein Ac45 (ATP6AP1 and
ATP6S1) plays amajor role in navigating the V-ATPase around
prostate carcinoma cells, as it does in the secretory pathway of
neuroendocrine cells (49). The question is as follows. Does
Ac45 facilitate transport to the plasma membrane, internaliza-
tion from the plasmamembrane, or both stages in the transport
process? Ac45 does function in clathrin-coated vesicle forma-
tion and clathrin-mediated endocytosis (79), with internaliza-
tion from the plasma membrane mediated via recognition
sequences in its 26-residue cytoplasmic tail (80). Consistent
with a function in guiding the V-ATPase to the plasma mem-
brane, mutations in this same cytoplasmic tail lead to failure to
recruit a3-containing V-ATPase to the ruffled membrane of
osteoclasts (48). Ac45 transgene expression has furthermore
been shown to cause V-ATPase accumulation at the plasma
membrane (49). Consequently, roles in transport both to and
from the plasma membrane are supported, albeit in different
cell types. This is reiterated here in invasive prostate carcinoma
cells, although Ac45 depletion appears to have a predominant
effect on transit to the plasma membrane. The partial loss of
plasma membrane V-ATPase activity in Ac45-depleted cells
indicates a net decrease in V-ATPase transport to the plasma
membrane, although we have been unable to determine
whether just a1 or both a1 and a3 isoforms are affected. How-
ever, based on their shared contribution to the overall JH in
PC-3 cells, both are likely to be affected to some extent. Most
significantly, Ac45 knockdown also arrests recycling of Tf and
TfR. During chase experiments, the morphology and organiza-
tion of transferrin-loaded vesicles in Ac45-depleted cells was
very similar to that in control cells, suggesting that Tf-TfR was
retained at a relatively late stage in the recycling process by
failing to exit the ERC or linked to a function of Ac45 in late-
stage exocytosis (50). Incomplete knockdown of a1 or a3 had
similar effects to Ac45 depletion on recycling of TfR, but the
differences in vesicle morphology resulting from these knock-
down experiments implies that they affect the process at a dif-
ferent earlier stage. Ac45 depletion also had some effect on the
kinetics of internalization of TfR and the a1 isoform, slowing
their removal from the plasma membrane, again consistent
with the reported effects of V-ATPase subunit depletion on
endocytosis (79). We therefore conclude that although Ac45 is
an important factor in navigating the V-ATPase through the
endosomal system, the effect of its knockdown is not simply due
to a failure to bring the acidifying enzyme to the correct com-
partment. Instead, its role is in targeting the V-ATPase to the
correct place in the late stages of membrane fusion during
exocytosis. If Ac45 is a significant factor in navigating the
V-ATPase to the plasma membrane, enhanced expression
could be responsible for maintaining the high levels of surface
V-ATPase activity in cancer cells.
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